CTOR compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

CTORCitius Oncology, Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

CTORCitius Oncology, Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

CTOR2 of 4 reports

Reportimpliedrealized× implied

Oct 27 '26—▲+2.57%—

Q3 FY26—▼−18.66%—

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedCTOR realized, solidLLY realized, hatchedOne scale, both sides: full bar = 19%× = |realized| ÷ impliedspan: CTOR 71d · LLY 267dSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

CTORCitius Oncology, Inc.

0.52· pre 0.52· delayed

Mkt cap$54.0MRevenue$1MQ3 FY26Revenue—

LLYELI Lilly & Co

1,371.32· pre 1,346.00· delayed

Pre-marketNov 6 '26delayed

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

Pre-marketNov 6 '26delayed

CTORCitius Oncology, Inc.

LLYELI Lilly & Co

0.52pre 0.52delayed

Price

1,371.32pre 1,346.00delayed

$54.0M

Mkt cap

$1.2T

Q3 FY26$1M

Revenue

$24.4BQ3 FY26

—

Revenue

$65.2BFY25

CTOR0.52vsLLY1,371.32Pre-marketNov 6 '26delayed